Selection of primary breast cancer patients for adjuvant endocrine therapy - Is oestrogen receptor alone adequate?

Breast Cancer Research and Treatment

Volumn 65, Issue 2, 2001, Pages 155-162

  Cheung, K L ^a   Nicholson, R I ^b   Blamey, R W ^a   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Tenovus Cancer Research Centre   (United Kingdom)

Author keywords

Adjuvant endocrine therapy; Breast cancer; ER

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FOLLOW UP; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; OVARIECTOMY; PATIENT SELECTION; PRIORITY JOURNAL;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; RECEPTORS, ESTROGEN; SURVIVAL RATE;

EID: 0035127466     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006430401243     Document Type: Article

References (36)

1. The surgical implications of estrophile protein estimations in carcinoma of the breast
2. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer
3. Estrogen receptor assay in primary breast cancer and early recurrence of the disease
4. Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy
5. The value of estrogen and progesterone receptors in the treatment of breast cancer
6. Oestrogen receptors and survival in early breast cancer
7. Steroid-hormone receptors in survival after first relapse in breast cancer
8. Prognostic significance of oestrogen and progesterone receptor activities in breast cancer
9. Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases
10. Estrogen receptor - A prognostic factor in breast cancer
11. Changes in multiple or sequential estrogen receptor determinations in breast cancer
12. A prognostic index in primary breast cancer
13. The Nottingham Prognostic Index in primary breast cancer
14. Assessment of response to therapy in advanced breast cancer
15. Steroid receptors in early breast cancer: Value in prognosis
16. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer
17. Assessment of response to treatment in advanced breast cancer
18. Survival patterns in hormone treated advanced breast cancer
19. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy
20. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy
21. Predictors of response to second-line endocrine therapy for breast cancer
22. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
23. The importance of stable disease in breast cancer patients treated with endocrine therapy
24. Estrogen receptor immunocytochemical assay (ER-ICA): Computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas
25. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples
26. Oestrogen-receptor status and sites of metastases in breast cancer
27. Oestrogen receptors, sites of melastatic disease and survival in recurrent breast cancer
28. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: A retrospective study
29. Primary hormone therapy of advanced breast cancer with megestrol acetate: Predictive value of estrogen receptor and progesterone receptor levels
30. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis
31. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer
32. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
33. EMSI gene expression in primary breast cancer: Relationship to cyclin D1 and oestrogen receptor expression and patient survival
34. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
35. Overexpression of c-erbB 2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
36. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary node metastases